title: Reply to H.J. Lee et al.
authors.affiliation: Cross Cancer Institute, Edmonton, Alberta, Canada john.mackey@trioncology.org.
authors.forename: John R
authors.initials: JR
authors.lastname: Mackey
authors.affiliation: Translational Research in Oncology, Edmonton, Alberta, Canada.
authors.forename: Vincent
authors.initials: V
authors.lastname: Houé
authors.affiliation: Translational Research in Oncology, Edmonton, Alberta, Canada.
authors.forename: Francois
authors.initials: F
authors.lastname: Thireau
authors.affiliation: Translational Research in Oncology, Edmonton, Alberta, Canada.
authors.forename: Mary-Ann
authors.initials: MA
authors.lastname: Lindsay
authors.affiliation: Translational Research in Oncology, Edmonton, Alberta, Canada.
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Fresco
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal